Anterior cervical discectomy and fusion (ACDF) is a commonly performed and safe procedure for cervical radiculopathy and/or myelopathy. [4] [5] [6] The primary goals of this procedure are to achieve adequate neural decompression and provide permanent segmental stabilization. An expected side effect of this operation is some loss of motion (although minimal with 1-or 2-level ACDF) and the possibility of developing pseudarthrosis or adjacentsegment degeneration. Although a cervical plate has been shown to decrease the incidence of postoperative complications related to the interbody graft and assist in maintaining lordosis, it too can be associated with complications such as screw backout, plate fracture, and dislodgment.
1,2 Motion-sparing procedures such as the use of arthroplasty have the advantage of maintaining the disc space height with the potential advantage of retaining some degree of cervical motion and perhaps decreasing the incidence of adjacent-segment degeneration. However, there is no strong evidence to support improved outcomes with the use of cervical arthroplasty.
The study by Upadhyaya et al. 7 in this issue of the Journal of Neurosurgery: Spine combines the data of 3 recently performed, industry-supported, randomized controlled trials (Prestige ST trial [Medtronic] , Bryan disc trial [Medtronic] , and the ProDisc-C trial [Synthes]) comparing the clinical outcomes of patients undergoing single-level arthroplasty or single-level ACDF. This analysis includes a total of 1213 patients (621 in the arthroplasty group and 592 in the ACDF group) from multiple centers across the US with at least a 24-month followup. All 3 trials included adult patients with single-level symptomatic and medically intractable radiculopathy and/or myelopathy due to cervical spondylosis between C-3 and C-7. Patients were excluded for severe spondylosis and limitation of neck motion. The follow-up rates were 94% and 87% for the arthroplasty and the ACDF groups, respectively. No statistical difference was observed between the 2 groups with regard to the neck disability index (NDI), 36-Item Short Form Health Survey Mental and Physical Component Summaries (SF-36 MCS and PCS), neck pain, or arm pain scores at the 24-month follow-up. However, segmental sagittal motion was preserved, and the incidence of a second operation was reduced, particularly for adjacent-segment degeneration. In addition, there was a statistically significant increase in "neurological success," which indicated a maintenance or improvement in neurological status via motor, sensory, or reflex examinations.
There are several positive aspects of this study: 1) The analysis included a large number of patients with information being extracted from source data.
2) The patient demographics and inclusion and exclusion criteria were relatively uniform across the 3 studies.
3) The outcome scales used are validated and appropriate. 4) A high follow-up rate was achieved. There are also several important limitations to this study: 1) The time interval of 24 months is relatively short, and longer follow-up would be required to assess the durability of the treatment arms.
2) The lack of blinding in the original studies allows for introduction of surgeon and patient bias perhaps favoring arthroplasty. 3) Although the original studies had heterogeneity in reporting adverse events, the lack of this information limits us in arriving at any strong conclusions.
Furthermore, cost associated with arthroplasty is not discussed and is certainly an important factor when considering the widespread use of this implant. The authors found that the incidence of surgery for adjacent-level degeneration was decreased when assuming a fixed effects model but not a random effects model. Although the justification for using a fixed effects model is presented in the Discussion, we argue that assuming a random effects model is more appropriate in this case, especially when the outcome is on the cusp of reaching statistical significance. As mentioned correctly in the manuscript, this model assumes heterogeneity in the studied population. Although the original randomized controlled trials Editorial See the corresponding article in this issue, pp 216-228.
were powered to demonstrate noninferiority, the lack of achieving statistically significant differences in outcome on the validated tools despite the relatively large combined number of patients raises concerns regarding the clinical significance even if a statistically significant difference was found with a larger study population.
It can be concluded that both ACDF and cervical arthroplasty provide excellent outcomes at the 24-month follow-up. The arthroplasty group has preserved segmental motion, but its clinical significance is uncertain. By design, arthroplasty eliminates the possibility of pseudarthrosis, but based on this analysis, it may not result in a decreased incidence of adjacent-segment degeneration.
In conclusion, the authors of this well-written and well-presented paper are to be congratulated for making an important and timely contribution to the literature. Based on the paper by Upadhyaya et al., cervical arthroplasty appears to be a good alternative for patients with symptomatic cervical radiculopathy and minimal cervical spondylosis. However, it is clear that longer follow-up is required to determine the durability of this motion-sparing procedure. Furthermore, standardized and well-reported adverse events data are required prior to fully supporting the widespread use of cervical arthroplasty. 3 Future efforts, ideally incorporating an international study design, should include longer follow-up data with the statistical power to assess the possible superiority of this treatment option to the routinely used and durable option of ACDF.
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Several issues merit clarification. First, they suggest that a major limitation of this study is the lack of blinding of the patients and surgeons. However, blinding the patients and surgeons is not practical. Patients reasonably expect to know what treatment they had and to be able to view their radiographs postoperatively. Few patients will consent to participate in a trial in which they are not told what treatment they received until 2 years postoperatively. Furthermore, surgeons cannot be blinded to the treatments that they perform.
It should be noted that although imperfect, the Level I data generated by these cervical arthroplasty studies are superior to the vast majority of data in the cervical spine literature, which is typically Level II or III at best. Although these studies are industry sponsored, they were closely regulated by the US Food and Drug Administration (FDA). The trials were conducted at centers that were randomly audited by the FDA. This level of scrutiny is far more stringent than single-center studies previously reported in the literature.
Second, there is the issue concerning the lack of long-term follow-up. However, it should be noted that the 5-year results of the PRESTIGE FDA investigational device exemption (IDE) trial paper have been recently published. 1 The 541 patients enrolled in this trial make up the largest cohort in the 3 reported US FDA IDE trials, consisting of 45% of the patients in this combined analysis. The results of the 5-year report (fewer secondary surgeries for arthroplasty) are consistent with the current combined analysis at 2 years. There is no doubt that longer-term follow-up remains an issue. However, the earliest application of cervical artificial discs can be traced back to the 1980s by Dr. Cummins in the United Kingdom, and there have not been high revision rates reported from the United Kingdom. 2, 7, 8 The third issue they raise is adverse event reporting, which was too heterogeneous for analysis, but this information is individually detailed in the papers published so far on the 3 arthroplasty trials.
